21/07/2026 Nektar Therapeutics initiated the Phase 3 ZENITH AD Program evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis Nektar Therapeutics initiated the Phase 3 ZENITH AD Program evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis (Ref) Nektar Therapeutics announced the initiation of the two global registrational Phase 3, ZENITH AD-1 and ZENITH AD-2 trials evaluating rezpegaldesleukin (IL-2 receptor agonist) in patients who were ≥12 year